IP Library › Granted Patent US 11,634,468
Granted Patent B2
US 11,634,468 · App. 16/776,107 · Granted Apr 25, 2023

Parathyroid hormone variants

Inventors: Clark Pan (Sudbury, MA); Angela Norton (Reading, MA); Kevin Holmes (Belmont, MA); David Bruce Lloyd (Leland, NC); Bryan James Goodwin (Lexington, MA); Rongxin Shi (Waltham, MA); Sujit Jain (Lexington, MA); Chuan Shen (West Roxbury, MA)
Assignee: SHIRE-NPS PHARMACEUTICALS, INC.
C07K14/635A61K9/0014A61P5/18C07K1/165A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,634,468
App. No.
16/776,107
Granted
Apr 25, 2023
Kind
B2
Abstract

The invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising same. The invention further relates to PTH compositions with improved serum half-life and peak-trough ratios, and methods of controlling serum calcium levels with the PTH variants and compositions of the invention. The invention further relates to methods of treating hypoparathyroidism and/or hypocalcemia due to hypoparathyroidism with the PTH variants and compositions of the invention.

Claims (5)

1. A parathyroid hormone (PTH)-Fc fusion protein, wherein the PTH-Fc fusion protein is PTH-66 having the amino acid sequence of SEQ ID NO: 8.

2. The PTH-Fc fusion protein of claim 1 , wherein the PTH-Fc fusion protein is glycosylated.

3. A pharmaceutical composition comprising the PTH-Fc fusion protein of claim 1 and a pharmaceutically acceptable carrier.

4. A pharmaceutical dosage form comprising the PTH-Fc fusion protein of claim 1 .

5. The pharmaceutical dosage form of claim 4 , wherein the dosage form is a liquid dosage form suitable for administration by injection or infusion.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2023
From: TAKEDA PHARMACEUTICALS U.S.A., INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 063977/0474 →
MERGER AND CHANGE OF NAME Recorded Mar 14, 2023
From: SHIRE-NPS PHARMACEUTICALS, INC.; TAKEDA PHARMACEUTICALS U.S.A., INC.
To: TAKEDA PHARMACEUTICALS U.S.A., INC.
Reel/Frame 062980/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: PAN, CLARK; NORTON, ANGELA; HOLMES, KEVIN; LLOYD, DAVID BRUCE; GOODWIN, BRYAN JAMES; SHI, RONGXIN; JAIN, SUJIT; SHEN, CHUAN
To: SHIRE-NPS PHARMACEUTICALS, INC.
Reel/Frame 055948/0608 →
Continuity (4)
Provisional Application 62798113 · Jan 29, 2019
Provisional Application 62800744 · Feb 4, 2019
Provisional Application 62884730 · Aug 9, 2019
Related Publication 20200247865A1 · Aug 6, 2020
Cited By (1)
US 12,291,556